Unknown

Dataset Information

0

FTY720 (fingolimod) increases vascular tone and blood pressure in spontaneously hypertensive rats via inhibition of sphingosine kinase.


ABSTRACT:

Background and purpose

FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical trials have demonstrated that this drug modestly increases BP. We previously showed that inhibition of sphingosine kinase increases vascular tone and BP in hypertensive, but not normotensive rats. Since FTY720 is reported to have inhibitory effects on sphingosine kinase, we investigated whether FTY720 increases vascular tone and BP only in hypertensive rats via this mechanism.

Experimental approach

The contractile and BP modulating effects of FTY720 were studied in vivo and ex vivo (wire myography) in age-matched normotensive Wistar Kyoto (WKY) rats and spontaneously hypertensive rats (SHRs).

Key results

Oral administration of FTY720 induced an increase in mean arterial pressure in SHR, whereas a decrease in BP was observed in WKY rats, as measured 24 h after administration. Similar to the sphingosine kinase inhibitor dimethylsphingosine (DMS), FTY720 induced large contractions in isolated carotid arteries from SHR, but not in those from WKY. In contrast, the phosphorylated form of FTY720 did not induce contractions in isolated carotid arteries from SHR. FTY720-induced contractions were inhibited by endothelium denudation, COX and thromboxane synthase inhibitors, and by thromboxane receptor antagonism, indicating that (like DMS-induced contractions) they were endothelium-dependent and mediated by thromboxane A?.

Conclusions and implications

These data demonstrate that FTY720 increases vascular tone and BP only in hypertensive rats, most likely as a result of its inhibitory effect on sphingosine kinase.

SUBMITTER: Spijkers LJ 

PROVIDER: S-EPMC3417456 | biostudies-literature | 2012 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

FTY720 (fingolimod) increases vascular tone and blood pressure in spontaneously hypertensive rats via inhibition of sphingosine kinase.

Spijkers Léon J A LJ   Alewijnse Astrid E AE   Peters Stephan L M SL  

British journal of pharmacology 20120601 4


<h4>Background and purpose</h4>FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical trials have demonstrated that this drug modestly increases BP. We previously showed that inhibition of sphingosine kinase increases vascular tone and BP in hypertensive, but not normotensive rats. Since FTY720 is reported to have inhibitory effects on sphingosine kinase, we investigated whether FTY720 increases vascular tone and BP  ...[more]

Similar Datasets

| S-EPMC4813727 | biostudies-other
| S-EPMC3646787 | biostudies-literature
| S-EPMC5147996 | biostudies-literature
| S-EPMC6150404 | biostudies-literature
| S-EPMC8720857 | biostudies-literature
| S-EPMC6274417 | biostudies-literature
| S-EPMC2803054 | biostudies-literature
| S-EPMC10502128 | biostudies-literature
| S-EPMC5112311 | biostudies-literature
| S-EPMC5107133 | biostudies-literature